Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
Vivoryon Therapeutics N.V. (VVY), a clinical stage company specializing in small molecule medicines development, has announced its upcoming 2025 Annual General Meeting. The meeting is scheduled for Tuesday, June 24, 2025 at 1:00 PM CEST and will be held at NautaDutilh N.V.'s Amsterdam offices. The company, which focuses on modulating pathologically altered proteins, has made the complete agenda and related documents available on their corporate website.
Vivoryon Therapeutics N.V. (VVY), un'azienda in fase clinica specializzata nello sviluppo di farmaci a piccole molecole, ha annunciato la sua prossima Assemblea Generale Annuale 2025. L'incontro si terrà martedì 24 giugno 2025 alle 13:00 CEST presso gli uffici di NautaDutilh N.V. ad Amsterdam. L'azienda, che si concentra sulla modulazione di proteine patologicamente alterate, ha reso disponibile l'intero ordine del giorno e i documenti correlati sul proprio sito web aziendale.
Vivoryon Therapeutics N.V. (VVY), una empresa en fase clínica especializada en el desarrollo de medicamentos de pequeñas moléculas, ha anunciado su próxima Junta General Anual 2025. La reunión está programada para el martes 24 de junio de 2025 a la 1:00 PM CEST y se llevará a cabo en las oficinas de NautaDutilh N.V. en Ámsterdam. La compañía, que se enfoca en modular proteínas alteradas patológicamente, ha puesto a disposición la agenda completa y los documentos relacionados en su sitio web corporativo.
Vivoryon Therapeutics N.V. (VVY)는 소분자 의약품 개발을 전문으로 하는 임상 단계 회사로, 다가오는 2025년 연례 주주총회를 발표했습니다. 회의는 2025년 6월 24일 화요일 오후 1시 CEST에 NautaDutilh N.V.의 암스테르담 사무실에서 개최됩니다. 병리학적으로 변형된 단백질 조절에 주력하는 이 회사는 전체 의제와 관련 문서를 자사 공식 웹사이트에 게시했습니다.
Vivoryon Therapeutics N.V. (VVY), une société en phase clinique spécialisée dans le développement de médicaments à petites molécules, a annoncé sa prochaine Assemblée Générale Annuelle 2025. La réunion est prévue pour le mardi 24 juin 2025 à 13h00 CEST et se tiendra dans les bureaux de NautaDutilh N.V. à Amsterdam. L'entreprise, qui se concentre sur la modulation des protéines pathologiquement altérées, a mis à disposition l'ordre du jour complet ainsi que les documents associés sur son site web corporate.
Vivoryon Therapeutics N.V. (VVY), ein klinisch fortgeschrittenes Unternehmen, das sich auf die Entwicklung von Wirkstoffen mit kleinen Molekülen spezialisiert hat, hat seine bevorstehende Jahreshauptversammlung 2025 angekündigt. Die Versammlung findet am Dienstag, den 24. Juni 2025 um 13:00 Uhr MESZ in den Büros von NautaDutilh N.V. in Amsterdam statt. Das Unternehmen, das sich auf die Modulation pathologisch veränderter Proteine konzentriert, hat die vollständige Tagesordnung und die zugehörigen Unterlagen auf seiner Firmenwebsite veröffentlicht.
- None.
- None.
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting
on June 24, 2025
Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2025 Annual General Meeting will be held on Tuesday, June 24, 2025 at 01:00 p.m. (CEST) at the Amsterdam offices of NautaDutilh N.V.
The full agenda and all relevant documents are available on the Company's website: https://www.vivoryon.com/2025-annual-general-meeting/.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When and where is Vivoryon Therapeutics (VVY) holding its 2025 Annual General Meeting?
Where can shareholders find the agenda for Vivoryon's 2025 AGM?
What is Vivoryon Therapeutics' main business focus?
What is Vivoryon's stock symbol and where is it traded?
